Chromatin and gene regulation during development
- Vasco Meneghini
- Tristan Félix
- Giacomo Frati
- Megane Brusson
- Anne Chalumeau
- Sophie Ramadier
- Giulia Hardouin
- Chiara Casotti
- Panagiotis Antoniou
Lattanzi A, Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem/Progenitor Cells for Therapeutic Genomic Rearrangements. Mol Ther. 2018 Oct 17. pii: S1525-0016(18)30497-0. doi: 10.1016/j.ymthe.2018.10.008.
Weber L., An optimized lentiviral vector corrects efficiently the human sickle cell disease phenotype. Mol Ther Methods Clin Dev. 2018 Aug 4;10:268-280. doi: 10.1016/j.omtm.2018.07.012. eCollection 2018 Sep 21.
Antoniani C. Induction of fetal hemoglobin synthesis in human erythroblasts by CRISPR/Cas9-mediated editing of the β-globin locus. (Comment on the article by Montbleau KE and Sankaran VG: Blood. 2018 Apr 26;131(17):1884-1885. doi: 10.1182/blood-2018-03-839787) Blood. 2018 Mar 8. pii: blood-2017-10-811505. doi: 10.1182/blood-2017-10-811505. F1000Prime recommended.
Lagresle-Peyrou C. Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion. (Comment on the article by. Hsieh MM and John F. Tisdale JF: Haematologica. 2018 Feb22.doi:10.3324/haemato Haematologica. 2018 Feb22.pii:haematol.2017.184788.doi: 10.3324/haematol.2017.184788.
Romano O., Transcriptional, epigenetic and retroviral signatures identify regulatory regions involved in hematopoietic lineage commitment. Scientific Reports, 2016, Apr 20;6:24724. doi: 10.1038/srep24724
The laboratory of Chromatin and gene regulation during development studies two main areas:
1) Dynamics of transcriptional and epigenetic networks during stem cell development
The definition of regulatory regions controlling the gene expression programs is fundamental for understanding the molecular mechanisms underlying many diseases and for the development of novel therapeutic approaches. Indeed, numerous disease-associated sequence variations occur in cis regulatory elements, which represent in some cases potential therapeutic targets. The aim of our projects is the genome-wide definition of the regulatory sequences used by human hematopoietic and epidermal stem/progenitor cells and their lineage-restricted progeny at different stages of development (Cavazza A., et al., Stem Cell Reports. 2016; Romano O. et al., Scientific Reports, 2016). The definition of the genetic and epigenetic programs was achieved through the use of a number of genomic and bioinformatic tools, including RNA-seq, deepCAGE, Retroviral scanning and ChIP-Seq. The outcome of this research is a better understanding of the molecular basis of stemness and lineage commitment of clinically relevant stem cells, which provides a knowledge basis for safer and more efficient usage of stem cells in cell and gene therapy (Romano O. et al., J Vis Exp. 2017; Romano O. et al., Stem Cells Translational Medicine, 2017).
Currently, we are analyzing genome-wide the occupancy of hematopoietic transcription factors (e.g., GATA1 and GATA2) and their co-factors, and the epigenetic histone modifications associated to transcription or silencing to define regulatory regions involved in hematopoietic stem cell biology and in erythroid commitment and differentiation. Validation of putative regulatory regions is performed by CRISPR-Cas9 targeted disruption and chromatic conformation capture assays (Romano et al., in preparation; Meneghini et al., in preparation).
2) Molecular-based approaches for the treatment of β-Hemoglobinopathies
Sickle cell disease (SCD) and β-thalassemias are genetic diseases caused by mutations in the gene coding for the adult hemoglobin β-chain. They represent the most common monogenic disorders worldwide, affecting thousands of newborns annually. In β-thalassemia, the reduced production of adult β-chains causes α-globin precipitation and red blood cell death. In SCD, a single aminoacid substitution in the β-globin chain leads to polymerization of the sickle hemoglobin (HbS) and red blood cell deformation. β-globin disorders may lead to a severe clinical phenotype characterized by anemia, pain crises, and organ damage. So far, the only curative treatment is represented by bone marrow transplantation from a compatible donor, which, however, is available to less than 30% of the patients. Experimental treatments include gene therapy and pharmacological intervention. In the latter approach, efforts are underway to identify compounds that raise the expression of the fetal g-globin genes. The rational for this treatment is based on the long-standing observation that patients harboring mutations that trigger elevated g-globin expression, experience a more benign clinical course of the disease (Cavazzana, Antoniani and Miccio, Molecular Therapy, 2017). However, pharmacological treatments are not equally effective for all patients, are associated with a considerable toxicity and do not represent a definitive treatment. Several nuclear factors, such as the erythroid master regulator GATA1, its cofactors FOG1 and BCL11A and the NuRD repressor complex, are implicated in the silencing of g-globin expression. However, their role in erythroid development and hemoglobin switching has yet to be completely elucidated.
The goal of our research is to provide the basic scientific knowledge for developing safe therapies for SCD and β-thalassemias based on lentiviral and genome editing approaches aimed at increasing g-globin expression. We aim at characterizing the transcription factors and the regulatory genomic elements that control the switch from fetal to adult globin gene expression. The fine mapping of regulatory elements involved in hemoglobin switching can provide potential targets for therapeutic induction of fetal hemoglobin. Our studies are focused on the molecular mechanisms underlying the β-to-g-globin switching as well as on the evaluation of the efficacy and safety of these therapeutic approaches. We apply established and novel molecular techniques (e.g. genome-wide genomic analyses, lentiviral and CRISPR/Cas9 technologies) by using different cellular models, including clinically relevant hematopoietic stem cells (Antoniani, Meneghini et al., Blood, 2018; Lagresle-Peyrou C. et al., Haematologica. 2018; Lattanzi et al., Molecular Therapy, 2018; Weber et al., Molecular Therapy and Clinical Development, 2018; Weber et al., in preparation; Meneghini Ramadier et al., in preparation).